Sanofi-Aventis (NYSE:SNY): Closing price $48.92
Sanofi’s subsidiary Genzyme says that the FDA has accepted for review its supplemental Biologics License Application file requesting approval of Lemtrada (alemtuzumab) for treating relapsing multiple sclerosis. The firm also reported key highlights from the domestic launch of once-daily, oral Aubagio (teriflunomide).
Markets are at 5-year highs! Discover the best stocks to own. Click here for our fresh Feature Stock Pick now!